当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Imcivree (setmelanotide)
申请企业
RHYTHM PHARMACEUTICALS INC
药品名称
Imcivree (setmelanotide)
承诺描述
Conduct a thorough QT trial to evaluate the effect of setmelanotide on the QTc interval. Design and conduct the trial in accordance with the ICH E14 guidance entitled, E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for NonAntiarrhythmic Drugs, and its Questions and Answers (R3).